Covid-19 Pandemisinde ve Öncesinde Başvuran Böbrek Tümörü Hastalarının Özelliklerinin Karşılaştırılması

Öz

Renal hücreli kanser tüm yetişkin kanserlerinin %2-3'ünü oluşturmaktadır. 2018 yılında dünya genelinde 415,000 yeni vaka tespit edilmiştir ve 180,000 vakada renal hücreli kanser nedeniyle hayatını kaybetmiştirPandemisi sürecinde böbrek kanseri tanısı konan hastalar yatarak tedavi edilmesi halinde SARS-CoV-2 enfeksiyonuna yakalanma ve enfeksiyona bağlı ölüm riski ile karşı karşıya kalma ihtimalleri yüksek idi.Çalışmamızda pandemi öncesi ve sonrasında böbrek tümörlerinin özelliklerindeki değişiklikleri ve operasyon sonuçlarını karşılaştırmayı planladık.

Anahtar Kelimeler

• Böbrek
• Pandemi
• Covid-19

Proje Numarası

SÜKAEK 2023 9/8

Comparison of the Characteristics of Kidney Tumor Patients Before and During the COVID-19 Pandemic

Öz

Renal cell carcinoma accounts for 2-3% of all adult cancers. In 2018, there were 415,000 new cases worldwide, and 180,000 patients died from renal cell carcinoma. During the pandemic, patients diagnosed with kidney cancer who required hospitalization faced a higher risk of contracting SARS-CoV-2 and death related to the infection. In our study, we aimed to compare the changes in the characteristics of kidney tumors and surgical outcomes before and after the pandemic.

Anahtar Kelimeler

• kidney
• pandemic
• covid-19

Destekleyen Kurum

Samsun Üniversitesi Klinik Araştırma Etik Kurulu

Proje Numarası

SÜKAEK 2023 9/8

Kaynakça

1. 1. Sandeep Anand Padala, Adam Barsouk, Krishna Chaitanya Thandra, and et al. Epidemiology of Renal Cell Carsinoma World J.Oncol 2020;11(3)70-87.
2. 2. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203-5.
3. 3. Vasudev NS, Wilson M, Stewart GD, Adeyoju A, and et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ open. 2020;10(5):e035938.
4. 4. Sacco E, Pinto F, Sasso F, and et al. Paraneoplastic syndromes in patients with urological malignancies. Urologia internationalis. 2009;83(1):1-11.
5. 5. Burki TK. Cancer guidelines during the COVID-19 pandemic. The Lancet Oncology. 2020;21(5):629-30.
6. 6. Naspro R, Da Pozzo LF. Urology in the time of corona. Nature Reviews Urology. 2020;17(5):251-3.
7. 7. Liang W, Guan W, Chen R, and et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The lancet oncology. 2020;21(3):335-7.
8. 8. Kuderer NM, Choueiri TK, Shah DP, and et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The Lancet. 2020;395(10241):1907-18.

9. 9. Zequi SdC, Abreu D. Consideration in the management of renal cell carcinoma during the COVID-19 Pandemic. International braz j urol. 2020;46:069-78.
10. 10. Mehrazin R, Smaldone MC, Kutikov A, and et al. Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance. The Journal of urology. 2014;192(3):659-64.
11. 11. Shiff B, Breau RH, Patel P, and et al. Impact of time to surgery and surgical delay on oncologic outcomes for renal cell carcinoma. The Journal of Urology. 2021;205(1):78-85.
12. 12. Kriegmair MC, Bertolo R, Karakiewicz PI, and et al. Systematic review of the management of local kidney cancer relapse. European Urology Oncology. 2018;1(6):512-23.
13. 13. Méjean A, Ravaud A, Thezenas S, and et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. New England Journal of Medicine. 2018;379(5):417-27.